One-Month Transplacental Pharmacokinetics of Raltegravir in a Premature Newborn after Short-Course Treatment of the HIV-1-Infected Mother | Zendy

C. Clavel-Osorio | Zendy; François Cazassus | Zendy; Stephani Stegmann | Zendy; Patricia Huc-Anaïs | Zendy; D. Lecam | Zendy; G. Peytavin | Zendy

Open Access

One-Month Transplacental Pharmacokinetics of Raltegravir in a Premature Newborn after Short-Course Treatment of the HIV-1-Infected Mother

Author(s) -

C. Clavel-Osorio,

François Cazassus,

Stephani Stegmann,

Patricia Huc-Anaïs,

D. Lecam,

G. Peytavin

Publication year - 2013

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01349-13

Subject(s) - raltegravir , transplacental , lopinavir , pharmacokinetics , medicine , context (archaeology) , human immunodeficiency virus (hiv) , pediatrics , pharmacology , virology , pregnancy , fetus , viral load , placenta , antiretroviral therapy , biology , paleontology , genetics

We describe the pharmacokinetics of raltegravir of a preterm newborn after short-course treatment of the mother tested HIV + the day of delivery. At age 1 month, the circulating concentration of raltegravir in the newborn was 29 ng/ml (the IC95 of RAL against HIV-1 is 15 ng/ml). Raltegravir should therefore be considered a potential transplacental postexposure prophylaxis for HIV-1 and an alternative to the use of boosted lopinavir in this context.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research